Keyword search

Sort Help
entries

Results

All (57)

All (57) (10 to 20 of 57 results)

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88-003-X20060029246
    Geography: Canada
    Description:

    While firms engaged in R&D services are part of the population of firms covered by the Research and Development in Canadian Industry (RDCI) survey and the Biotechnology Use and Development Survey (BUDS), this industry group is not covered by a typical industry survey. This means that there are no industry-specific figures for contribution to GDP or other typical measures of industrial activities and finances. However, data for the industry group are available from the Survey of Innovation 2003, along with other selected professional services. Data from that survey indicate that the establishments in R&D services in physical, engineering and life sciences may be part of a select and highly atypical group of firms and are discussed in this article.

    Release date: 2006-06-27

  • Articles and reports: 88-003-X20050028021
    Geography: Canada
    Description:

    Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

    Release date: 2005-06-20

  • Articles and reports: 88F0006X2005010
    Description:

    This paper looks into Canadian innovative biotechnology firms' access to financing capital. Results show that over 70% of biotech firms that attempted to raise financing capital were successful. Funds were primarily sought for R&D activities and came primarily from Canadian venture capitalists. Harsher market conditions were the main reasons put forward by investors to limit or reject biotechnology firms' funding requests.

    Release date: 2005-04-29

  • Articles and reports: 88F0006X2005009
    Description:

    The main indicators of biotechnology activities in Canada are presented in this article. The data are from the 2003 Biotechnology Use and Development Survey. Within the last few years, except for the number of employees with biotechnology-related responsibilities that remained stable, an increase in all the indicators was noticed. For example, the number of innovative firms involved in biotechnology activities rose from 375 in 2001 to 490 in 2003 and biotechnology revenues rose from $3.6 billion to $3.8 billion between 2001 and 2003. Also, biotechnology R&D spending increased by 11% between 2001 and 2003 and the amount of capital raised for biotechnology was up 73% during this period.

    Release date: 2005-04-27

  • Articles and reports: 88-003-X20050017771
    Geography: Canada
    Description:

    Preliminary data indicate the biotechnology sector continued its phenomenal growth in Canada between 2001 and 2003, generating almost $4 billion in revenues. Biotechnology companies have more than quadrupled their revenues since 1997, making biotech a quickly growing activity.

    Release date: 2005-02-09

  • Articles and reports: 88-003-X20040037427
    Geography: Canada
    Description:

    A series of working papers on the transition from small to medium size is being derived from a joint project of Statistics Canada and the National Research Council's Industrial Research Assistance Program (NRC-IRAP). The project developed out of a need to better understand how and why certain businesses grow.

    Release date: 2004-10-29

  • Articles and reports: 88-003-X20040037432
    Geography: Canada
    Description:

    This article is based on a recent series of interviews with leaders of high growth biotechnology firms. It highlights the importance of financing, management strategies and qualified personnel for achieving high growth.

    Release date: 2004-10-29

  • Articles and reports: 88-003-X20040037436
    Geography: Canada
    Description:

    This study examined the difference in adoption rates between firms that reported high employment growth and firms that did not.

    Release date: 2004-10-29

  • Articles and reports: 88-003-X20040037437
    Geography: Canada
    Description:

    This analysis gives some insights into how small firms that have made the transition to medium size are different from the rest of the pack in innovativeness, patent use, confidentiality agreements, and research and development tax credits collaboration. It is based on the 1999 Survey of Innovation.

    Release date: 2004-10-29
Data (3)

Data (3) ((3 results))

Analysis (54)

Analysis (54) (0 to 10 of 54 results)

  • Articles and reports: 88F0006X2007007
    Description:

    Results from the Survey of Innovation 2003 raised some interesting questions. First, an unexpected one-third of establishments in R&D services were not innovative. According to the guidelines of the Oslo Manual, innovative establishments are those that introduced a new or significantly improved product or process on to the market or into production, within a specified interval. Second, many of these non-innovative establishments indicated that satisfying existing customers was irrelevant to their firms success. This was very different response from all other types of firms.

    This working paper provides a potential explanation of these unexpected results, as well as an overview of available information on establishments in R&D services (NAICS 5417) in the context of professional services generally. The paper assembles descriptive data to show that non-innovative establishments in R&D services differ significantly from other non-innovative establishments and, while not innovative, they are nevertheless highly inventive. It presents some evidence to suggest that they are venture firms (firms relying on infusions of investment capital rather than revenues from sales to sustain their operations) and proposes a specific set of indicators that would facilitate resolution of the nature of firms in this industry group.

    Release date: 2007-12-20

  • Articles and reports: 88F0006X2007006
    Description:

    This descriptive working paper provides highlights from the Biotechnology Use and Development Survey 2005. Data on innovative biotechnology firms are presented by region, sectors and firm size. The data include firm revenues, R&D activities, human resources, firm financing, age of firms, country of control and the proportion of publicly traded firms.

    Release date: 2007-12-05

  • Articles and reports: 88-003-X200700210323
    Geography: Canada
    Description:

    Although nanotechnology can be thought of as a sector of its own, it is clear that nanotechnology is a cross-sector phenomenon with potentially significant impacts. Nanotechnologies can be found in areas as diverse as biotechnology and health, agriculture, electronics and computer technology, environment and energy, optics, and in materials and manufacturing.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210324
    Geography: Canada
    Description:

    Statistics Canada is actively involved with the international community in developing statistical information on nanotechnologies. This article summarizes the ongoing work of the OECD's newly-established Working Party on Nanotechnology, with particular emphasis on the role of Statistics Canada.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210325
    Geography: Canada
    Description:

    Innovative biotechnology firms are science-based firms which attempt to bring an application of biotechnology to the market. However, it is clear that a significant proportion of these firms derive no revenue from product sales while their products proceed through the various phases of testing and regulatory approval. In order to support their operations they must look to other sources of funding.

    Release date: 2007-10-09

  • Articles and reports: 88-003-X200700210326
    Geography: Canada
    Description:

    Although private investors and government funding agencies have learned that the biotechnology sector requires a funding model different from that of traditional manufacturing, there is a paucity of empirical research investigating the links between characteristics of the funding model and firm performance. The purpose of this article is to examine which funding sources have the greatest influence on firm growth.

    Release date: 2007-10-09

  • Articles and reports: 88F0006X2007005
    Description:

    This working paper provides results from a pilot survey on nanotechnology, which was appended to the Biotechnology Use and Development Survey 2005. The paper presents the conceptual issues and survey challenges relating to measurement of nanotechnology-related activities, as well as preliminary data on nanotechnology firms in Canada.

    Release date: 2007-08-31

  • Articles and reports: 88-003-X20070019620
    Geography: Canada, Province or territory
    Description:

    Preliminary data from the Biotechnology Use and Development Survey (BUDS) 2005 indicate that growth continued in the sector, but at a slower pace than has been reported in earlier years. This article highlights some key biotechnology indicators for innovative biotech firms in Canada, by sector, size and province.

    Release date: 2007-05-10

  • Articles and reports: 88-003-X20060029246
    Geography: Canada
    Description:

    While firms engaged in R&D services are part of the population of firms covered by the Research and Development in Canadian Industry (RDCI) survey and the Biotechnology Use and Development Survey (BUDS), this industry group is not covered by a typical industry survey. This means that there are no industry-specific figures for contribution to GDP or other typical measures of industrial activities and finances. However, data for the industry group are available from the Survey of Innovation 2003, along with other selected professional services. Data from that survey indicate that the establishments in R&D services in physical, engineering and life sciences may be part of a select and highly atypical group of firms and are discussed in this article.

    Release date: 2006-06-27

  • Articles and reports: 88-003-X20050028021
    Geography: Canada
    Description:

    Between 1997 and 2003, the number of innovative biotechnology firms rose from 282 to 490. Biotechnology in Canada continued to expand between 2001 and 2003, generating revenues of almost $4 billion. Biotechnology companies have more than quadrupled their revenues since 1997, making biotechnology a fast growing activity.

    Release date: 2005-06-20
Reference (0)

Reference (0) (0 results)

No content available at this time.

Date modified: